Correction to: Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists

Drug Saf. 2019 Jul;42(7):919. doi: 10.1007/s40264-019-00830-5.

Authors

Rasmus M Christensen¹, Christian R Juhl¹, Signe S Torekov²

Affiliations

¹ Department of Biomedical Sciences and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen N, Denmark.
² Department of Biomedical Sciences and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen N, Denmark. [email protected].

PMID: 31041671
DOI: 10.1007/s40264-019-00830-5

Abstract

In the original publication of this article, the following correction should be noted in Table 1.

Publication types

Published Erratum